BAI1: from cancer to neurological disease.

Brain-specific Angiogenesis Inhibitor 1 (BAI1) is a member of the adhesion G protein-coupled receptor (GPCR) sub-family and is mainly expressed in the brain. Structurally, BAI1 has a large N-terminus containing five thrombospondin type 1 repeats (TSR), a putative hormone-binding domain and a GPCR-Autoproteolysis Inducing (GAIN) domain encompassing a GPCR-proteolytic site [1]. The C-terminus of BAI1 contains a proline-rich region and a terminal Gln-Thr-Glu-Val (QTEV) PDZ-binding motif, which associates with a number of scaffolding proteins involved in intracellular signaling [1]. BAI1's TSR are required for functions as varied as the phagocytosis of apoptotic cells by macrophages, myogenesis, and the inhibition of angiogenesis (Figure ​(Figure1)1) [1]. Cleavage of the BAI1 N-terminus releases soluble 40 and 120 kDa peptides called vasculostatins, for their anti-angiogenic activity. Overexpression of BAI1 or vasculostatin-120 can inhibit tumor growth in several cancer xenograft models in vivo [1]. Whether the tumor suppressor function of BAI1 is entirely dependent on its extracellular TSRs, or also involves its emerging intracellular signaling activity is currently unclear. The human BAI1 gene is located on chromosome 8q24 and its expression is epigenetically silenced in glioma. In addition, recent discoveries have shown that the genes encoding BAI1, BAI2 and BAI3 undergo somatic mutations in several cancers, including lung, breast, ovarian and brain, suggesting that they might be tumor suppressors [1]. To further explore whether BAI1 loss might be linked to tumor development, we recently generated a line of Bai1-knockout (Bai1−/−) mice. The mutant mice are viable and fertile, obtained at the expected Mendelian ratio and have no obvious anatomical defects [2]. Aging the mice did not evidence any increase of cancer incidence, suggesting that loss of Bai1 expression is not sufficient to induce tumor formation per se [2]. More work is needed to define whether a cancer susceptibility role for BAI1 will only be revealed when combined with alterations in other pro-tumorigenic loci. Figure 1 Multiple functions of BAI1 In the brain, BAI1 is enriched in neurons at the postsynaptic density (PSD), an electron-dense thickening in the postsynaptic membrane that contains over 100 synaptic proteins and regulates the strength of the excitatory signal, a phenomenon called synaptic plasticity. This suggests that BAI1 might serve as a critical regulator of synapse development, maturation and maintenance. To test this hypothesis, we used neurophysiological techniques to provide electrical stimulations to neurons in hippocampal synapses of the Bai1−/− mice and found strikingly enhanced long-term potentiation (LTP) and impaired long-term depression (LTD) [2]. LTP and LTD are the most widely studied types of synaptic plasticity and are believed to underlie multiple forms of learning and memory. Consistently, the Bai1−/− mice show severely impaired spatial learning and memory in the hidden-platform version of the Morris water maze task [2]. Synaptic plasticity can also be associated with changes in dendritic spine morphology. BAI1 interacts with a variety of proteins that exert powerful effects on dendritic spine formation. For example, BAI1-associated protein 2 (BAIAP2), also called insulin receptor substrate 53 (IRSp53), is a Rho family GTPase effector and has essential roles in filopodia formation and neuronal development [3]. Knockdown of BAIAP2 by short interfering RNAs reduces the density, length, and width of dendritic spines in neuron cultures [4]. Similarly, acute BAI1 knockdown results in a ∼50% reduction in spine density of cultured neurons [5]. Based on these results, we expected changes in the density or morphology of dendritic spines of neurons in the Bai1−/− brains. Surprisingly, we did not detect any significant changes in spine formation and/or maturation in Bai1−/− CA1 pyramidal neurons. These data suggest that morphological changes induced by BAI1 loss in dendritic spines are only observed under in vitro conditions, or that compensatory effects take place in vivo during development. Exploring the mechanisms underlying the deficits of synaptic plasticity in the Bai1−/− mice, we found that Bai1 deficiency promotes a rapid degradation of PSD-95, a major PSD scaffolding protein, and virally-mediated restoration of PSD-95 in the Bai1−/− hippocampus is sufficient to normalize synaptic plasticity [2]. This, along with the observation that Bai1−/− mice and the Psd95- mutant mice show strikingly similar phenotypes, suggest that the deficits observed in the Bai1−/− mice are due, at least in part, to loss of Bai1-induced PSD-95 stability. Our results have wide-ranging implications for a variety of neurodegenerative diseases. For example, Alzheimer's disease (AD) is a neurological disorder characterized by the abnormal aggregation of the amyloid beta component of the amyloid precursor protein (APP), yet APP's endogenous function remains largely unknown. Reduction in PSD-95 is among the earliest changes in synaptic composition in the APP mutant neurons [6], suggesting that dysregulation of PSD-95 may underlie AD pathogenesis. Recent studies from genome-wide transcriptome analyses indicate that BAI family mRNA expression is downregulated in large cohorts of AD patients [7]. These results, along with our observations, provide a rationale to expand the exploration of BAI1's contribution to disease pathogenesis beyond cancer, including in neurological diseases such as AD.